Literature DB >> 31532829

Development and validation of a 1.5 T MR-Linac full accelerator head and cryostat model for Monte Carlo dose simulations.

M Friedel1, M Nachbar1, D Mönnich1, O Dohm1,2, D Thorwarth1.   

Abstract

PURPOSE: To develop, implement, and validate a full 1.5 T/7 MV magnetic resonance (MR)-Linac accelerator head and cryostat model in EGSnrc for high precision dose calculations accounting for magnetic field effects that are independent from the vendor treatment planning system.
METHODS: Primary electron beam parameters for the implemented model were adapted to be in accordance with measured dose profiles of the Elekta Unity (Elekta AB, Stockholm, Sweden). Parameters to be investigated were the mean electron energy as well as the Gaussian radial intensity and energy distributions. Energy tuning was done comparing depth dose profiles simulated with monoenergetic beams of varying energies to measurements. The optimum radial intensity distribution was found by varying the radial full width at half maximum (FWHM) and comparing simulated and measured lateral profiles. The influence of the energy distribution was investigated by comparing simulated lateral and depth dose profiles with varying energy spreads to measured data. Comparison of simulations and measurements was performed by calculating average and maximum local dose deviations. The model was validated recalculating a clinical intensity-modulated radiation therapy plan for the MR-Linac and comparing the resulting dose distribution with simulations from the commercial treatment planning system Monaco using the gamma criterion.
RESULTS: Comparison of simulated and measured data showed that the optimum initial electron beam for MR-Linac simulations was monoenergetic with an electron energy of (7.4 ± 0.2) MeV. The optimum Gaussian radial intensity distribution has a FWHM of (2.2 ± 0.3) mm. The average relative deviations were smaller than 1% for all simulated profiles with optimum electron parameters, whereas the largest maximum deviation of 2.07% was found for the 22 × 22 cm 2 cross-plane profile. Profiles were insensitive to energy spread variations. The IMRT plan recalculated with the final MR-Linac model with optimized initial electron beam parameters showed a gamma pass rate of 99.83 % using a gamma criterion of 3%/3 mm.
CONCLUSIONS: The EGSnrc MR-Linac model developed in this study showed good accordance with measurements and was successfully used to recalculate a first full clinical IMRT treatment plan. Thus, it shows the general possibility for future secondary dose calculations of full IMRT plans with EGSnrc, which needs further detailed investigations before clinical use.
© 2019 The Authors. Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Keywords:  MR-linac; Monte Carlo simulations; magnetic resonance guided radiotherapy

Mesh:

Year:  2019        PMID: 31532829     DOI: 10.1002/mp.13829

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  4 in total

1.  Evaluation of MU2net as an online secondary dose check for MR guided radiation therapy with the Elekta unity MR linac.

Authors:  Ariadne S Shoobridge; John A Baines
Journal:  Phys Eng Sci Med       Date:  2022-04-05

2.  Imaging science and development in modern high-precision radiotherapy.

Authors:  Daniela Thorwarth; Ludvig Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2019-12-09

3.  Influence of beam quality on reference dosimetry correction factors in magnetic resonance guided radiation therapy.

Authors:  Stefan Pojtinger; Marcel Nachbar; Ralf-Peter Kapsch; Daniela Thorwarth
Journal:  Phys Imaging Radiat Oncol       Date:  2020-10-27

4.  Automatic 3D Monte-Carlo-based secondary dose calculation for online verification of 1.5 T magnetic resonance imaging guided radiotherapy.

Authors:  Marcel Nachbar; David Mönnich; Oliver Dohm; Melissa Friedlein; Daniel Zips; Daniela Thorwarth
Journal:  Phys Imaging Radiat Oncol       Date:  2021-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.